

NASDAQ: RCEL ASX: AVH

Accelerating Our Growth Profile

Investor Presentation August 2023

Forward-Looking Statements & Legal Disclaimers




Certain statements in this presentation and the accompanying oral commentary are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, technology platform, development strategy, prospective products, pipeline and milestones, regulatory objectives, expected payments from and outcomes of collaborations, and likelihood of success, are forward-looking statements. Such statements are predictions only and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, among others, the costs, timing and results of clinical trials and other development activities; the uncertainties inherent in the initiation and enrollment of clinical trials; the uncertainties associated with the COVID-19 pandemic; the unpredictability of the timing and results of regulatory submissions and reviews; market acceptance for approved products and innovative therapeutic treatments; competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; and possible safety or efficacy concerns, general business, financial and accounting risks and litigation. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. More information concerning AVITA Medical as well as the aforementioned risks and uncertainties is available in our public filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K for the year ended December 31, 2022 and subsequently filed Quarterly Reports on Form 10-Q. We are providing this information as of its date and do not undertake any obligation to update or revise it, whether as a result of new information, future events or circumstances or otherwise, except as required by law. Additional information may be available in press releases or other public announcements and public filings made after the date of this presentation.

AVITA Medical's products are Rx only. Please reference the Instructions for Use for more information on indications, contraindications, warnings, precautions and adverse events.

In the United States, RECELL® is approved for use in patients suffering acute thermal burns. Use of RECELL in other patient populations is either prohibited by United States law or may be made available pursuant to a relevant investigational device exemption granted by the FDA (and likewise limited by United States law to investigational use only).





Spray-On Skin Cells contain cells necessary to regenerate patient's outer layer of natural, healthy skin as well as cells that modulate and **catalyze healing process**




Current U.S. Indications: Thermal burn wounds and full-thickness skin defects Repigmentation of stable depigmented vitiligo lesions

Core Advantages:

- Utilizes small skin sample from patient; significantly less skin relative to conventional skin graft treatment
- Suspension created at patient's bedside within 30 minutes, further supports healing at the cellular level
- Multi-cell regenerative therapy in single point-of-care procedure, reducing hospital length of stay

What is RECELL?






In the U.S., RECELL is approved for thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited.

One Platform. Multiple Indications.





Highlights and Milestones

COMMERCIAL REVENUE GROWTH

• Second quarter 2023: 42% same quarter prior year

FIELD SALES ORGANIZATION

- Initiated recruiting and hiring process; grew from 30 to 69 towards goal of 70
- Onboarding and training underway and ahead of schedule

FULL-THICKNESS SKIN DEFECTS ("FTSD")

- Received FDA approval on June 7, 2023
- Commenced commercial launch on June 8, 2023

VITILIGO

- FDA approval on June 16, 2023
- Pursing site of service reimbursement for the use of RECELL in office, which is expected in 2025

RECELL GO DEVICE

- FDA submission on June 30, 2023
- Expect FDA approval by December 27, 2023
- FDA Breakthrough Device Designation



Full-Thickness Skin Defects Opportunity



RECEIVED FDA APPROVAL ON JUNE 7, 2023

BROADENED LABEL OF FTSD INCLUDES AFTER TRAUMATIC AVULSION (E.G., DEGLOVING), SURGICAL EXCISION (E.G., NECROTIZING SOFT TISSUE INFECTION), OR RESECTION (E.G., SKIN CANCER)



INITIATED COMMERCIAL LAUNCH ON JUNE 8, 2023

>

SIGNIFICANT SYNERGIES BETWEEN BURNS AND FULL-THICKNESS SKIN DEFECTS DRIVES GROWTH OVER THE NEXT 3+ YEARS

FDA approval of FTSD encompasses a broad set of wounds

In the U.S., RECELL is approved for thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited.

Female, pregnant 28-year-old who suffered from a de-gloving injury



Full-Thickness Skin Defects: Market Sizing




Market Size Prior to FDA Approval ¹			Additional Market Opportunity with FDA Approved Expanded Indication of FTSD ¹				
 Traumatic Wounds Degloving (Open Wounds) Crush Abrasion Laceration Puncture 	99,000 2,000 5,000 10,000 2,000		Wounds t Wounds ic Hematoma	Data pending	 Surgical Wounds Muscle-only Flap Laparotomy Abdominoplasty Dehiscence Hidradenitis Suppurativa 	Data pendin	
 Surgical Wounds Necrotizing Fasciitis Amputation Fasciotomy 	2,000 6,000 1,000	• Cancer E	c ision - Canc Excision	: er 136,000	 Chronic Wounds DFU VLU Non - Pressure Ulcers Pressure Ulcers 	21,000 42,000 51,000 14,000	
~127,000 Eligible Pro	cedures		> 264	4,000 Eliç	jible Procedures		

Total market opportunity of traumatic, surgical, cancer excision & chronic wounds ~391,000 annual eligible procedures

(1) Market size derived from third-party claims reports and internal analysis based on skin graft CPT codes tied to diagnosis code of specified wound types.



FULL-THICKNESS SKIN DEFECTS INDICATION MEANINGFUL BROADENS BUSINESS



Total eligible procedures at targeted call points: 420,000+

FTSD UTILIZES IN-PATIENT REIMBURSEMENT:

Same DRG code as burns; effective immediately

FTSD UTILIZES OUT-PATIENT TRANSITIONAL PASS-THROUGH CODE (TPTC):

Same code as burns; effective immediately

OF ~150 BURN CENTERS, 50% ARE ALSO TRAUMA CENTERS

Immediate access to expanded label upon approval

APPROXIMATELY 30% OF BURNS ARE TREATED OUTSIDE OF BURN CENTERS WITHIN TRAUMA CENTERS

Expansion into these trauma centers allows sales force to capture remaining portion of burn market Value Analysis Committee discussions in trauma centers started in April 2023

SAME SALES FORCE

Expanded commercial organization from 30 to 70, ahead of launch of FTSD

GROWTH

Synergies enhanced commercial launch of FTSD on June 8 AVITA Medical growth over the next three to five years **FUELED BY FTSD AND BURNS IN THE UNITED STATES AND INTERNATIONALLY**



RECELL Device Evolution





FIRST GENERATION DEVICE

• Fully manual cell disaggregation





- Fewer steps and streamlined workflow, allowing for faster set up
- Reduces time of procedure

RECELL GO DEVICE

₩ RECELLGC

• Fully automated cell disaggregation and filtration

0

AVIT

- Simple user interface with timer count-down
- Reusable base unit plus singleuse sterile cartridge

Vitiligo Opportunity



RECEIVED FDA APPROVAL ON JUNE 16, 2023 WITH STUDY RESULTS:

- Primary endpoint: proportion of study sites achieving ≥80% repigmentation for RECELL-treated sites vs control at week 24
- Super-superiority was established for the primary endpoint (p<0.025)



RECELL INDICATION REPRESENTS FIRST-IN-CLASS RE-PIGMENTATION TRANSPLANTATION OF MELANOCYTES



PLANS FOR 2023 - 2024:

• Conduct post-market study of ~100 patients to demonstrate both the repigmentation and mental health benefits of vitiligo treatment



MARKET GREATER THAN BURNS AND FULL-THICKNESS SKIN DEFECTS, COMBINED

• Vitiligo opens significant market application of RECELL



SITE OF SERVICE REIMBURSEMENT FOR RECELL IN OFFICE EXPECTED 2025

In the U.S., RECELL is approved for thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited.

Patient from a prior study at six-months RECELL-treated area was 100% re-pigmented



Komen L, Vrijman C, Tjin EP, Krebbers G, de Rie MA, Luiten RM, van der Veen JW, Wolkerstorfer A. Autologous cell suspension transplantation using a cell extraction device in segmental vitiligo and piebaldism patients: a randomized controlled pilot study. Journal of the American Academy of Dermatology. 2015 Jul;73(1):170-2.

* NB-UVB protocol per Vitiligo Working Group recommendations JAAD 2017.

р 12

2023: A Year of Inflection





FULL-THICKNESS SKIN DEFECTS

- Received FDA approval on June 7
- ~5x market expansion will fuel revenue growth



VITILIGO

- Received FDA approval on June 16
- Patient population greater than burns and fullthickness skin defects, combined;
- Pursuing reimbursement for RECELL in physician setting

>

RECELL GO


- Submitted FDA supplement on June 30, 2023
- Expecting FDA approval by December 27, 2023



INTERNATIONAL STRATEGY EXPANSION

• Communicating with Q3 earnings release





(1) Approximately 500,000 patients with vitiligo sought treatment in 2022.


In the U.S., RECELL is approved for thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited.

Financial Overview

Ryan



	Full-Year Ended	Three-Mon	ths Ended
(USD in \$000s)	2022	March 31	June 30
Commercial Sales	34,051	10,458	11,686
BARDA Sales	370	92	67
Total Revenue	34,421	10,550	11,753
Gross Profit	28,380	8,883	9,549
Gross Profit %	82%	84%	81%
Growth Rate %	36%	40%	42%
Cash, Cash Equivalents & Marketable Securities	86,272	77,640	68,801
Shares outstanding	25,208,436	25,327,761	25,447,615



		l		
ss Osborn, Cantor (U.S.)	Brooks O'Neil, Lake Street (U.S.) John Hester, Bell Potter (AUS) Lyanne Harrison, BofA Global Research (AUS)	 Scott Power, Morgans (AUS) Chris Kallos, MST (AUS) Shane Storey, Wilsons (AUS) 	NASDAQ RCEL	ASX AVH

Looking Ahead

FINANCIAL GUIDANCE

COMMERCIAL REVENUE, EXCLUDING BARDA REVENUE:

- Q2 2023: \$13 \$14 million
- 2023: \$51 \$53 million

GROSS PROFIT MARGIN:

• 2023: 83% TO 85%

FUTURE MILESTONES

- Anticipate FDA approval of RECELL GO by December 27, 2023
- Expect commercial launch of RECELL GO on January 2, 2024
- Expect commercial launch of vitiligo in 2025





Summary



BURNS

- Core burn centers will continue to penetrate, adopt and grow
- Burns utilization will expand, accessing ~30% of market not currently called on by AVITA Medical sales team
- Strong healthcare economics drive in-patient adoption; TPTC broadens coverage



FULL-THICKNESS SKIN DEFECTS

- Represents ~5x expansion of burn center market opportunity in level 1 and level 2 trauma centers
- Reimbursement started DAY 1 using same codes and reimbursement as burns



VITILIGO

- Represents patient population greater than burns and full-thickness skin defects, combined; opens significant market application
- Pursuing site of service reimbursement for RECELL within the physician setting, expected 2025



RECELL GO

- Evolutionary design of existing RECELL technology designed to automate cell disaggregation process; eases training burden
- Critical component of platform that will greatly accelerate our growth



OUTLOOK OVER NEXT 3 TO 5 YEARS IN U.S.

- Growth driven by burns and full-thickness skin defects
- RECELL GO expected to increase adoption rates across our indications
- Vitiligo comes to market in 2025
- Communicating international expansion strategy with Q3 earnings release



Transforming lives.